Effect of paroxetine and nefazodone on 5 H1A receptor sensitivity

被引:54
作者
Sargent, P [1 ]
Williamson, DJ [1 ]
Pearson, G [1 ]
Odontiadis, J [1 ]
Cowen, PJ [1 ]
机构
[1] UNIV OXFORD, LITTLEMORE HOSP, DEPT PSYCHIAT, OXFORD OX4 4XN, ENGLAND
基金
英国医学研究理事会;
关键词
5-HT1A receptor; gepirone; paroxetine; nefazodone;
D O I
10.1007/s002130050348
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Animal experimental studies suggest that the therapeutic effect of selective serotonin re-uptake inhibitors (SSRIs) may involve neuroadaptive changes in pre- and post-synaptic serotonin(1A) (5-HT1A) receptors. We used the endocrine and hypothermic responses to the 5-HT1A receptor agonist, gepirone (20 mg orally), to assess 5-HT1A receptor sensitivity in 37 healthy male volunteers who were studied before and following random double-blind, allocation to treatment with paroxetine, nefazodone or placebo for 17 days. Following antidepressant drug treatment, hypothermic responses to gepirone were markedly decreased by paroxetine but only slightly diminished by nefazodone. Paroxetine also lowered the growth hormone and cortisol responses to gepirone. There nas no change in either hypothermic or endocrine response following placebo treatment. Our results suggest that paroxetine treatment produces a striking attenuation of measures of both pre-and post-synaptic 5-HT1A receptor function. Nefazodone appears to decrease the sensitivity of 5-HT1A autoreceptors to some extent and this effect may contribute to its antidepressant activity.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 42 条
[31]  
PRICE LH, 1989, ARCH GEN PSYCHIAT, V46, P625
[32]  
SALAZAR DE, 1994, CLIN PHARMACOL THER, V55, P55
[33]  
SELETTI B, 1995, NEUROPSYCHOPHARMACOL, V13, P93
[34]   ELECTROPHYSIOLOGICAL RESPONSES OF SEROTONINERGIC DORSAL RAPHE NEURONS TO 5-HT1A AND 5-HT1B AGONISTS [J].
SPROUSE, JS ;
AGHAJANIAN, GK .
SYNAPSE, 1987, 1 (01) :3-9
[35]   RESPONSES OF HIPPOCAMPAL PYRAMIDAL CELLS TO PUTATIVE SEROTONIN 5-HT1A AND 5-HT1B AGONISTS - A COMPARATIVE-STUDY WITH DORSAL RAPHE NEURONS [J].
SPROUSE, JS ;
AGHAJANIAN, GK .
NEUROPHARMACOLOGY, 1988, 27 (07) :707-715
[36]  
TAYLOR DP, 1995, J CLIN PSYCHIAT, V56, P3
[37]  
TULLOCH IF, 1992, J CLIN PSYCHIAT, V53, P7
[38]  
VANDEKAR LD, 1991, ANNU REV PHARMACOL, V31, P289
[39]  
VANDEKAR LD, 1995, 2 INT C NEW DIR AFF
[40]   EFFECTS OF FLUOXETINE TREATMENT OF PLATELET H-3 IMIPRAMINE BINDING, 5-HT UPTAKE AND 5-HT CONTENT IN MAJOR DEPRESSIVE DISORDER [J].
WAGNER, A ;
MONTERO, D ;
MARTENSSON, B ;
SIWERS, B ;
ASBERG, M .
JOURNAL OF AFFECTIVE DISORDERS, 1990, 20 (02) :101-113